Expert consensus on adverse reactions of targeted therapy for advanced thyroid cancer Consensus Formulation Unit:Chinese Anti-Cancer Association Thyroid Cancer Integrated Care Committee
ZHAO Jing
WANG Xin
GAO Jie
ZHAO Yiyuan
XU Xiaoxia
CAO Jiayan
MA Hongwen
JIN Aixiang
ZHAO Jie
ZHANG Fangyuan
WANG Shulang
CHEN Changlian
MA Fang
Abstract:Objective:To establish an expert consensus on adverse reactions of targeted therapy for advanced thyroid cancer.Methods:Chinese and international foreign databases and relevant guideline websites were retrieved.Relevant evidence was summarized and the quality of evidence was evaluated.The initial draft of expert consensus on adverse reactions of targeted therapy for advanced thyroid cancer was formed.China experts were organized to conduct two rounds of Delphi expert inquiry and one round of expert meeting.Based on the clinical experience of experts,the initial draft of expert consensus on adverse reactions of targeted therapy for advanced thyroid cancer was revised,and the experts had reached consensus.Then,the final expert consensus on adverse reactions of targeted therapy for advanced thyroid cancer was formed.Results:The evaluation and intervention of 7 common adverse reactions(rash,hand-foot skin reaction,oral mucosal inflammation,diarrhea,fatigue,nausea and vomiting,and hypertension)were included in the expert consensus on adverse reactions of targeted therapy for advanced thyroid cancer.Conclusions:The expert consensus on adverse reactions of targeted therapy for advanced thyroid cancer provides guidance for helping nursing staff evaluate and intervene in the adverse reactions of targeted therapy in patients with advanced thyroid cancer.
Keywords:thyroid cancertargeted therapyadverse reactionsnursingexpert consensus
Publication Date:2025-03-25
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:15( 881-895 )
Chinese Nursing Research

Chinese Nursing Research

ISTICPKU
ISSN:1009-6493
Year, Vol.(Issue):2025,39(6)